Mass. Movers

Alnylam releases trial results

Alnylam Pharmaceuticals Inc. released top-line results from its phase 2b trial for its treatment of respiratory syncytial virus, an infection in lung transplant patients. The Cambridge company said the trial was a randomized, double-blind, placebo-controlled study of the drug, ALN-RSV01, in infected lung transplant patients. “We believe that these data provide important evidence’’ of a reduction in the incidence of new disease in patients, said one Alnylam executive.